<DOC>
	<DOCNO>NCT00262522</DOCNO>
	<brief_summary>The purpose study compare safety tolerability to-be-marketed lopinavir/ritonavir ( LPV/r ) tablet formulation market soft gel capsule ( SGC ) formulation compare safety , tolerability , antiviral activity daily ( QD ) twice daily ( BID ) dose LPV/r tablet formulation combination select nucleoside reverse transcriptase inhibitor ( NRTIs ) patient previously receive antiretroviral treatment .</brief_summary>
	<brief_title>Study Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules Once Daily Versus Twice Daily Administration , When Coadministered With Nucleoside Reverse Transcriptase Inhibitors Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Subjects human immunodeficiency virus type 1 ( HIV1 ) positive , antiretroviral na√Øve adult least 18 year age &lt; 7 day prior antiretroviral therapy . Subjects plasma HIV1 ribonucleic acid ( RNA ) level &gt; = 1,000 copies/mL screen acutely ill . Female subject nonpregnant nonlactating . Exclusion Criteria Subjects exclude screen laboratory analysis show follow abnormal laboratory result : Presence hepatitis B surface antigen ( HBsAg ) Hemoglobin &lt; = 8.0 g/dL Absolute neutrophil count &lt; = 750 cells/microliter Platelet count &lt; = 50,000 per mL Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; = 3.0 x Upper Limit Normal ( ULN ) Calculated creatinine clearance &lt; 50 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Human Immunodeficiency Virus Infections</keyword>
</DOC>